Incyte Corporation: all 314 studies
Page 4 of 4. Open to participants first (38), then studies with results posted, then the rest; newest registration first within each.
- An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisCompletedNCT01633372Phase 2
- A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid ArthritisCompletedNCT01626573Phase 2
- A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedNCT01604889Phase 1/2
- Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast CancerTerminatedNCT01254136Phase 1/2
- A Dose-escalation Study in Subjects With Advanced MalignanciesCompletedNCT01195311Phase 1
- A Dose-escalation Study in Subjects With Advanced MalignanciesCompletedNCT01072266Phase 1
- Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast CancerTerminatedNCT00864175Phase 1/2
- Open-Label Study to Assess the Safety/Tolerability in Patients With Solid TumorsCompletedNCT00820560Phase 1
- Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 DiabetesTerminatedNCT00698789Phase 2
- Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 DiabeticsCompletedNCT00698230Phase 2
- Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic SubjectsCompletedNCT00478322Phase 2
- A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to DiabetesCompletedNCT00398619Phase 1
- Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected PatientsCompletedNCT00393120Phase 2
- Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIsTerminatedNCT00300573Phase 2